JPMorgan Chase & Company’s (NYSE:JPM) sidelined Chief Executive Jamie Dimon is proving to be hard to replace as a Street ‘champion’, as the environment at the top is being soured by public outrage along with increased regulation, according to Bloomberg. However, Dimon’s peer group has its own problems, which include tarnished reputations, weak performances, and their near refusal to step up to the plate.
Microsoft Corporation’s (NASDAQ:MSFT) Windows Phone handsets has grown in number by 312 percent worldwide since January, and by 273 percent domestically, says a study by Localytics, according to AllThingsD. Nokia Corporation’s (NYSE:NOK) share of the world Windows market has grown to almost 60 percent from approximately 22 percent of the market, but AllThingsD opines that even with this growth, the two firms’ market share is still insufficient to support the broader ambitions of either.
Pfizer Inc. (NYSE:PFE) reports that the FDA has extended the action date by three months for the New Drug Application for tofacitinib, which is an investigational oral treatment for adults suffering from moderately to severely active rheumatoid arthritis. Upon approval, the drug would be the first rheumatoid arthritis treatment in a new class of medicines known as Janus kinase inhibitors and also the first new oral disease-modifying antirheumatic drug for the disease in more than a decade. The FDA decided that additional data analyses recently submitted by Pfizer comprise a major modification to the application and will thus require additional time to evaluate. However, the agency has not requested any new studies of Pfizer, and has provided an anticipated Prescription Drug User Fee Act date of November 21, 2012.
Don’t Miss: Best Buy: WORST Week Ever?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.